Dr. Reddy’s Laboratories Ltd ADR (RDY) - Total Assets
Based on the latest financial reports, Dr. Reddy’s Laboratories Ltd ADR (RDY) holds total assets worth $562.90 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Dr. Reddy’s Laboratories Ltd ADR debt service capacity to assess how comfortably operating cash covers total debt obligations.
Dr. Reddy’s Laboratories Ltd ADR - Total Assets Trend (2000–2025)
This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's total assets have evolved over time, based on quarterly financial data. See Dr. Reddy’s Laboratories Ltd ADR (RDY) net assets for net asset value and shareholders' equity analysis.
Dr. Reddy’s Laboratories Ltd ADR - Asset Composition Analysis
Current Asset Composition (March 2025)
Dr. Reddy’s Laboratories Ltd ADR's total assets of $562.90 Billion consist of 50.7% current assets and 49.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $2.51 Billion | 3.0% |
| Accounts Receivable | $109.79 Billion | 22.3% |
| Inventory | $71.08 Billion | 14.4% |
| Property, Plant & Equipment | $96.98 Billion | 19.7% |
| Intangible Assets | $96.80 Billion | 19.6% |
| Goodwill | $11.81 Billion | 2.4% |
Asset Composition Trend (2000–2025)
This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Dr. Reddy’s Laboratories Ltd ADR.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dr. Reddy’s Laboratories Ltd ADR's current assets represent 50.7% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, up from 0.8% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 22.3% of total assets.
Dr. Reddy’s Laboratories Ltd ADR Competitors by Total Assets
Key competitors of Dr. Reddy’s Laboratories Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Dr. Reddy’s Laboratories Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.88 | 1.92 | 1.78 |
| Quick Ratio | 1.38 | 1.37 | 1.23 |
| Cash Ratio | 0.00 | 0.00 | 0.44 |
| Working Capital | $139.24 Billion | $121.07 Billion | $887.08 Million |
Dr. Reddy’s Laboratories Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Dr. Reddy’s Laboratories Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 27.2% |
| Total Assets | $492.99 Billion |
| Market Capitalization | $11.16 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Dr. Reddy’s Laboratories Ltd ADR's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dr. Reddy’s Laboratories Ltd ADR's assets grew by 27.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
The table below shows the annual total assets of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $492.99 Billion | +27.22% |
| 2024-03-31 | $387.52 Billion | +20.40% |
| 2023-03-31 | $321.85 Billion | +9.91% |
| 2022-03-31 | $292.83 Billion | +7964.18% |
| 2021-03-31 | $3.63 Billion | +18.28% |
| 2020-03-31 | $3.07 Billion | -98.64% |
| 2019-03-31 | $225.43 Billion | -0.08% |
| 2018-03-31 | $225.60 Billion | +2.63% |
| 2017-03-31 | $219.82 Billion | +5.86% |
| 2016-03-31 | $207.65 Billion | +6.62% |
| 2015-03-31 | $194.76 Billion | +14.42% |
| 2014-03-31 | $170.22 Billion | -88.04% |
| 2013-03-31 | $1.42 Trillion | +1091.60% |
| 2012-03-31 | $119.48 Billion | +25.76% |
| 2011-03-31 | $95.00 Billion | +18.27% |
| 2010-03-31 | $80.33 Billion | -4.13% |
| 2009-03-31 | $83.79 Billion | -1.93% |
| 2008-03-31 | $85.45 Billion | -0.79% |
| 2007-03-31 | $86.12 Billion | +25.24% |
| 2006-03-31 | $68.77 Billion | +134.80% |
| 2005-03-31 | $29.29 Billion | +9.79% |
| 2004-03-31 | $26.68 Billion | +15.86% |
| 2003-03-31 | $23.03 Billion | +21.53% |
| 2002-03-31 | $18.95 Billion | +60.02% |
| 2001-03-31 | $11.84 Billion | +7510.61% |
| 2000-03-31 | $155.57 Million | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more